Wellmarker Bio is a new drug development company that discovers and validates new targets based on unsatisfactory medical demand and develops anti-cancer drugs based on the predictive biomarker. Wellmarker Bio, a company that Professor Jin Dong-Hoon spun off from Asan Medical Center in December 2016, is developing five targeted anti-cancer drugs based on biomarkers for predicting treatment responses, and among them, targeted anti-cancer drugs and new electromagnetic immune antibodies anti-cancer drugs targeting colon cancer patients who do not comply with existing drugs are representative. It has signed a contract with the British technology agency, Pharmas Ventures, to export colorectal cancer treatments. Biomarker-based anti-cancer drug technology was published in the March 2020 issue of Biopharma Dilmakers under Nature. Currently, patient-specific anticancer drugs are being developed for various indications such as colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). WM-S1, a major pipeline of Wellmarkerbio, has completed a preclinical trial at Charles River, a targeted anti-cancer drug for colorectal cancer patients who are resistant to Erbitux. It is planning to enter the Phase 1 clinical trial in the U.S. within this year, and conducting research to expand its adaptability and receiving funding from Korea Drug Development Fund (KDDF).